What is the recommended griseofulvin dosing for children based on weight, including dosage amount, frequency, duration, and administration with meals?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Griseofulvin Dosing in Children

For children, administer griseofulvin at 15-20 mg/kg/day (single or divided dose) for those under 50 kg, or 1 g/day for those over 50 kg, given for 6-8 weeks, and always administer with a fatty meal to enhance absorption. 1

Weight-Based Dosing Algorithm

Standard Dosing (British Association of Dermatology Guidelines)

  • Children < 50 kg: 15-20 mg/kg/day for 6-8 weeks 1
  • Children > 50 kg: 1 g/day for 6-8 weeks 1
  • Dose frequency: Single daily dose or divided into 2 doses 1

FDA-Approved Dosing (Alternative Reference)

  • Children 30-50 lbs (13.6-22.7 kg): 125-250 mg daily 2
  • Children > 50 lbs (> 22.7 kg): 250-500 mg daily in divided doses 2
  • General pediatric guideline: 10 mg/kg/day 2

Critical Administration Requirements

Always give griseofulvin with fatty food - this is non-negotiable as it increases absorption by 70-120% depending on fat content 3. The FDA label specifically notes that administration with milk in pediatric patients resulted in 4-fold higher peak serum concentrations and 10-fold larger area under the curve compared to fasting administration 2.

Duration Considerations

  • Standard tinea capitis: 6-8 weeks 1
  • Microsporum infections: Full 8 weeks recommended (more effective than shorter courses) 1
  • Trichophyton infections: May require 12-18 weeks if standard treatment fails 1
  • Resistant cases: Doses up to 25 mg/kg/day may be necessary for prolonged periods 1

Important Clinical Nuances

Species-Specific Efficacy

Griseofulvin is significantly more effective against Microsporum species (88.5% response rate) than Trichophyton species (67.9% response rate) 1. For Trichophyton infections, consider terbinafine as first-line instead, though griseofulvin remains the only licensed treatment for tinea capitis in children in the UK 1.

Dose Escalation for Treatment Failures

Recent evidence from refugee populations shows that increasing griseofulvin to ≥30 mg/kg/day can achieve complete response in patients who showed only partial response to ≤25 mg/kg/day, with no significant adverse effects 4. This is particularly relevant for Trichophyton violaceum infections.

Common Pitfalls to Avoid

  1. Not giving with fatty food: This is the most common reason for treatment failure due to poor absorption
  2. Stopping treatment too early: Continue until mycological cure is achieved, not just clinical improvement 1
  3. Using inadequate doses for Trichophyton: Standard doses may be insufficient; don't hesitate to increase to 25-30 mg/kg/day 4
  4. Forgetting drug interactions: Rifampicin decreases plasma concentration; cimetidine increases it 1

Contraindications

  • Lupus erythematosus
  • Porphyria
  • Severe liver disease 1

Monitoring

The endpoint is mycological cure, not clinical cure - repeat mycology sampling until clearance is achieved 1. If clinical improvement occurs but mycology remains positive, continue therapy for an additional 2-4 weeks 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.